Source Fact: Financial Supervisory Service DART / 2026-03-31
Disclosure Type: Results of Annual General Shareholders Meeting
💡 3-Second Summary
Alteogen finalized its fiscal year 18th financial statements, locking in KRW 215.8B in consolidated revenue and KRW 106.9B in operating profit. Shareholders also approved all agendas, including its historic KRW 20B cash dividend and the establishment of an internal Audit Committee to enhance corporate governance.
📊 1. [Key Disclosure Details & Figures Summary]
- Date of Meeting: March 31, 2026
- Confirmed FY18 (2025) Financial Performance (Consolidated):
- Revenue: KRW 215,859 million (Approx. KRW 215.8B)
- Operating Profit: KRW 106,900 million (Approx. KRW 106.9B)
- Net Profit: KRW 145,173 million (Approx. KRW 145.1B)
- Earnings Per Share (EPS): KRW 2,653
- Audit Opinion: Clean/Unqualified (Both Separate and Consolidated)
- Approved Cash Dividend:
- Dividend Per Share: KRW 371 for both Common and Preferred shares
- Total Dividend Payout: KRW 20,003,180,288 (Approx. KRW 20B)
- Dividend Yield: 0.1%
- Major Approved Agendas:
- Amendments to Articles of Incorporation (Governance reorganization via Audit Committee establishment)
- Re-election of Executive Director Hang-Yeon Kim (CFO) and election of new independent audit committee members
- Reduction of capital surplus and transfer to retained earnings (securing dividend resources)
📈 2. [Expert Insight: Stock Price Impact Analysis]
- Solidifying Fundamental via Confirmed Three-Digit Operating Profit: Obtaining an unqualified audit opinion for these final figures completely defuses potential accounting risks often tied to the biotech sector. An operating profit of KRW 106.9B firmly signals that its milestone-driven revenue structure has successfully entered a self-sustaining, profitable orbit.
- Green Light for Active Shareholder Returns: Passing the KRW 20B dividend and the capital surplus transfer is a massive psychological catalyst for the market. While the 0.1% yield is modest, the symbolic act of an R&D-heavy biotech platform initiating cash dividends will significantly boost appeal for long-only institutional funds.
- Governance Rerating Through Audit Committee Setup: Rewriting articles to mandate an internal Audit Committee and recruiting prominent financial experts—including a former Korea Exchange (KRX) executive—upgrades the firm’s ESG profile. This move is a strategic prerequisite for a potential future KOSPI board transfer or global institutional fundraising, acting as a structural mid-to-long-term tailwind.
📝 Editor’s Comment (by K-STOCK Editor)
The outcome of this AGM proves that Alteogen has evolved into a highly mature, profitable biotech powerhouse. The re-election of CFO Hang-Yeon Kim, paired with the structural reduction of capital surplus to boost retained earnings, underscores a sophisticated corporate strategy focused on sustaining shareholder distributions. By checking all three critical boxes—accounting transparency, a multi-billion won dividend payout, and institutionalized governance upgrades—Alteogen has flawlessly demonstrated the premium qualities expected of a true market leader.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!